capital healthEli Lilly’s 3rd quarter earnings overlook and forecast Minimize bring on sharp stock fall Eli Lilly is dialing back again its 2024 forecast soon after underwhelming Wall Street with third-quarter earnings and revenue from two key prescription drugs that missed anticipations. [deltaMinutes] mins in the past Now × Our workforce is